After AstraZeneca and Daiichi Sankyo made waves in June with eye-opening results for Enhertu in a combination treatment for a ...

AstraZeneca and Daiichi Sankyo got U.S. approval to expand the label of their jointly developed Enhertu drug in combination with another medicine as an initial treatment for a type of breast cancer.

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's Enhertu in combination with Roche ...

AstraZeneca (AZN.L, AZN.ST) on Monday said Enhertu plus pertuzumab won approval in the US as the first-line treatment of ...

Drugmaker AstraZeneca chalked up two regulatory wins on Tuesday, with approvals in both the US and Europe for key treatments ...

(Alliance News) - AstraZeneca PLC on Monday said enhertu plus pertuzumab has been approved in the US as a first-line treatment of patients with HER2-positive metastatic breast cancer.

ENHERTU Plus Pertuzumab Approved in the U.S. for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer ...

AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has been approved in the US for the 1st-line treatment of adult patients with unresectable or ...

Daiichi Sankyo has emerged victorious in appeals court, flipping a prior multimillion-dollar patent verdict on its head and ...

The Food and Drug Administration (FDA) on Monday approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab deruxtecan or Dato-DXd) for adult patients with locally advanced or metastatic ...

AstraZeneca and its partner Daiichi Sankyo have obtained the Food and Drug Administration’s green light for Datroway to treat an advanced form of non-small cell lung cancer in adults who had received ...

The US Food and Drug Administration has approved Daiichi Sankyo's therapy in combination with Roche's drug for the first-line ...